Tag Archives: Annual Meeting

Business, Finance, Occupation & Industry

Glen Burnie Bancorp Declares 1Q Dividend

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Glen Burnie Bancorp Declares 1Q Dividend

GLEN BURNIE, Md.–(BUSINESS WIRE)– Glen Burnie Bancorp (NAS: GLBZ) , parent company of The Bank of Glen Burnie, today announced that on March 14, 2013 its Board of Directors declared a regular dividend of ten cents ($0.10) per share of common stock. This action marks the company’s 83rd consecutive dividend.

The regular dividend is payable on April 5, 2013 to shareholders of record at the close of business on March 29, 2013. As of March 15, 2013, Glen Burnie Bancorp had 2,736,978 common shares outstanding with approximately 415 shareholders of record.

Glen Burnie Bancorp will host its Annual Meeting of Stockholders at 2:30 p.m. on Thursday, May 9, 2013 at The Bank of Glen Burnie‘s Glen Burnie branch office at 101 Crain Highway, South in Glen Burnie, Maryland.

Glen Burnie Bancorp, parent company to The Bank of Glen Burnie®, currently maintains consolidated assets totaling more than $380 million. Founded in 1949, The Bank of Glen Burnie® is a locally-owned community bank with eight branch offices serving Anne Arundel County. (www.thebankofglenburnie.com)

Certain information contained in this news release, which does not relate to historical financial information, may be deemed to constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, which could cause the company’s actual results in the future to differ materially from its historical results and those presently anticipated or projected. For a more complete discussion of these and other risk factors, please see the company’s reports filed with the Securities and Exchange Commission.

Glen Burnie Bancorp
Yvonne “Rie” Atkinson
410-768-8857 (office)
ratkinson@bogb.net

KEYWORDS:   United States  North America  Maryland

INDUSTRY KEYWORDS:

The article Glen Burnie Bancorp Declares 1Q Dividend originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

…read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

XenoPort Announces Presentations at the American Academy of Neurology Meeting

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

XenoPort Announces Presentations at the American Academy of Neurology Meeting

SANTA CLARA, Calif.–(BUSINESS WIRE)– XenoPort, Inc. (NAS: XNPT) announced today that it will present the following posters at the 65th Annual Meeting of the American Academy of Neurology in San Diego, California:

AP (arbaclofen placarbil)

Spasticity

  • An Ongoing Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Arbaclofen Placarbil in Subjects with Spasticity Due to Multiple Sclerosis
    Session Info: Poster Session P03: March 19, 2:00 pm – 6:30 pm PT
    Poster #: P03.267
  • The Burden of Multiple Sclerosis-Related Spasticity on Indirect Costs and Requirement for Non-Professional Care: Results of a Cross-Sectional Study in the USA
    Session Info: Poster Session P03: March 19, 2:00 pm – 6:30 pm PT
    Poster #: P03.217
  • Impact of Spasticity on Healthcare Resource Utilisation: Results of a Cross-Sectional Study in the USA
    Session Info: Poster Session P03: March 19, 2:00 pm – 6:30 pm PT
    Poster #: P03.211

XP1279

Parkinson’s Disease

  • Double-Blind Study of an Actively-Transported Levodopa Prodrug, XP21279, in Parkinson Disease
    Session Info: Poster Session P02: March 19, 7:30 am – 12:00 pm PT
    Poster #: P02.075

XP23829

Preclinical and Phase 1 Studies

  • Comparative Gastric Irritation of the Fumaric Acid Esters Dimethyl Fumarate (DMF) and XP23829 in Rat and Monkey
    Session Info: Poster Session P01: March 18, 2:00 pm – 6:30 pm PT
    Poster #: P01.159
  • Favorable Metabolism and Pharmacokinetics of Formulations of XP32829, a Novel Fumaric Acid Ester, in Healthy Subjects
    Session Info: Poster Session P05: March 20, 2:00 pm – 7:00 pm PT
    Poster #: P05.189

…read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

New TYSABRI Data Reaffirm Substantial Efficacy in Treatment of People with MS and Demonstrate Stabil

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

New TYSABRI Data Reaffirm Substantial Efficacy in Treatment of People with MS and Demonstrate Stability of Anti-JCV Antibody Status

– Continued Research into Risk Stratification and PML Early Detection Provides Additional Insights for Physicians –

WESTON, Mass.–(BUSINESS WIRE)– Biogen Idec (NAS: BIIB) and Elan Corporation, plc (NYS: ELN) announced results from several studies of TYSABRI® (natalizumab) that demonstrate its efficacy compared to other multiple sclerosis (MS) treatments, provide additional data supporting anti-JC virus (JCV) antibody status stability, and suggest better outcomes when progressive multifocal leukoencephalopathy (PML) is detected early. These data will be presented at the 65th Annual Meeting of the American Academy of Neurology (AAN) in San Diego.

“These new data reinforce our belief in the substantial efficacy TYSABRI has demonstrated at both the early and advanced stages of relapsing forms of MS,” said Alfred Sandrock, M.D., Ph.D., senior vice president, Development Sciences and chief medical officer, Biogen Idec. “We are also encouraged by the consistency in anti-JCV antibody status demonstrated over 18 months, as well as results from our pursuit of additional paths to help mitigate the impact of PML. These combined efforts may allow a more individualized approach when selecting TYSABRI treatment, while helping physicians better understand a patient’s benefit-risk profile.”

Substantial TYSABRI Efficacy Demonstrated Against First-Line Therapies

In an independent statistical analysis led by Timothy Spelman and Helmut Butzkueven, M.D. at the University of Melbourne, with contribution by Fabio Pellegrini and Annie Zhang, TYSABRI demonstrated a significantly lower rate of first relapse compared to interferon beta (IFN) and glatiramer acetate (GA). This propensity-matched analysis was conducted using data from two MS patient registries: TYSABRI Observational Program (TOP) and MSCOMET. The results indicate that relapses were not only more likely to occur in patients taking IFN and GA, but that they occurred more quickly, when compared to patients taking TYSABRI (hazard ratio 2.73, 95 percent confidence interval 2.10-3.55, p<0.001).

  • Comparison of Patients Treated with Natalizumab and Interferon-Beta/Glatiramer Using Propensity-Matched Multiple Sclerosis Registry Data (P01.211) will be available for viewing on Monday, March 18, 2013 from 2:00 to 6:30 p.m. PDT

…read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Sturm, Ruger &amp; Company, Inc. to Host Tour of Its Manufacturing Facility in Prescott, Arizona

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Sturm, Ruger & Company, Inc. to Host Tour of Its Manufacturing Facility in Prescott, Arizona

SOUTHPORT, Conn.–(BUSINESS WIRE)– Sturm, Ruger & Company, Inc. (NYS: RGR) , announced today that it will be hosting a tour of its manufacturing facility located in Prescott, Arizona on Monday, April 29, 2013 at 2:00 p.m. MST for certain analysts, shareholders and other interested parties who express an interest in attending, subject to certain qualifying criteria. Space on this tour will be limited.

Analysts, shareholders and other interested parties who have an interest in attending the plant tour should submit a written request to Tom Dineen, Chief Financial Officer, no later than March 25, 2013, with their name, address, contact information, and the number of shares owned. Due to ITAR considerations, only citizens of the United States will be considered for the plant tour.

The Company will notify those persons it is able to accommodate for the plant tour no later than March 29, 2013. Because space for the plant tour is limited, only those persons who are notified by the Company will be permitted to attend the plant tour.

Analysts and shareholders that we are unable to accommodate for the plant tour are cordially invited to attend the Annual Meeting of Stockholders to be held at 9:00 a.m. MST on April 30, 2013 at the Hassayampa Inn, 122 East Gurley Street, Prescott, Arizona.

Sturm, Ruger & Company, Inc.
One Lacey Place
Southport, CT 06890
www.ruger.com
203-259-7843

KEYWORDS:   United States  North America  Arizona  Connecticut

INDUSTRY KEYWORDS:

The article Sturm, Ruger & Company, Inc. to Host Tour of Its Manufacturing Facility in Prescott, Arizona originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

(function(c,a){window.mixpanel=a;var b,d,h,e;b=c.createElement(“script”);
b.type=”text/javascript”;b.async=!0;b.src=(“https:”===c.location.protocol?”https:”:”http:”)+
‘//cdn.mxpnl.com/libs/mixpanel-2.2.min.js’;d=c.getElementsByTagName(“script”)[0];
d.parentNode.insertBefore(b,d);a._i=[];a.init=function(b,c,f){function d(a,b){
var c=b.split(“.”);2==c.length&&(a=a[c[0]],b=c[1]);a[b]=function(){a.push([b].concat(
Array.prototype.slice.call(arguments,0)))}}var g=a;”undefined”!==typeof f?g=a[f]=[]:
f=”mixpanel”;g.people=g.people||[];h=[‘disable’,’track’,’track_pageview’,’track_links’,
‘track_forms’,’register’,’register_once’,’unregister’,’identify’,’alias’,’name_tag’,
‘set_config’,’people.set’,’people.increment’];for(e=0;e<h.length;e++)d(g,h[e]);
a._i.push([b,c,f])};a.__SV=1.2;})(document,window.mixpanel||[]);
mixpanel.init("9659875b92ba8fa639ba476aedbb73b9");
…read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Signature Bank Announces Internet Availability of Annual Shareholders' Meeting Proxy Materials for F

Leave a comment

By Business Wirevia The Motley Fool

Filed under:


Signature Bank Announces Internet Availability of Annual Shareholders’ Meeting Proxy Materials for Fiscal Year 2012

NEW YORK–(BUSINESS WIRE)– Signature Bank (NAS: SBNY) , a New York-based full-service commercial bank, announced today that the Bank’s proxy materials for its 2013 Annual Meeting of Shareholders are now available via the Internet under the U.S. Securities and Exchange Commission’s Notice and Access Rule.

Under the Notice and Access rule, companies may furnish proxy materials to shareholders via the Internet as an alternative to the traditional mail delivery of printed materials. Shareholders as of the February 26, 2013 record date for the Annual Meeting will be mailed a “Notice Regarding the Availability of Proxy Materials.” This notice will provide the Internet web site address where the proxy materials can be viewed and shares can be voted. It will also include instructions for requesting a paper copy of the proxy materials via telephone, Internet web site or email. By implementing the Notice and Access Rule, Signature Bank was able to considerably reduce the number of printed copies of its annual report and proxy materials that it would produce, thereby lowering production and delivery costs as well as minimizing the impact on the environment from its Annual Meeting.

Signature Bank‘s 2013 Annual Meeting of Shareholders will be held on Wednesday, April 24, 2013 at 9:00 a.m. (Eastern Time) at The Roosevelt Hotel, 45 East 45th Street, New York, NY 10017, (212) 661-9600.

Signature Bank‘s 2012 annual report and proxy statement for the 2013 Annual Meeting can also be viewed on the Company’s web site by visiting http://investor.signatureny.com/annuals.cfm.

About Signature Bank

Signature Bank, member FDIC, is a New York-based full-service commercial bank with 26 private client offices throughout the New York metropolitan area. The Bank’s growing network of private client banking teams serves the needs of privately owned businesses, their owners and senior managers. Signature Bank offers a wide variety of business and personal banking products and services. The Bank operates Signature Financial, LLC, a specialty finance subsidiary focused on equipment finance and leasing, transportation financing and taxi medallion financing. Investment, brokerage, asset management and insurance products and services are offered through the Bank’s subsidiary, Signature Securities Group Corporation, a licensed broker-dealer, investment adviser and member FINRA/SIPC.

…read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

MGE Energy Issues March 2013 'Interim Report'

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

MGE Energy Issues March 2013 ‘Interim Report’

MADISON, Wis.–(BUSINESS WIRE)– MGE Energy, Inc. (NAS: MGEE) today published its investor newsletter Interim Report with the following topics:

…read more
Source: FULL ARTICLE at DailyFinance

 
– Dividend record remains strong
– MGEE reports earnings increase
– Annual Meeting planned for May 21
– MGEE stock performs well

– TheStreet gives MGEE top rating
– High Value Line rating
– Madison’s first public CNG fueling station
– Madison gets national recognition
Business, Finance, Occupation & Industry

RYTARYTM (IPX066) (Carbidopa and Levodopa) Extended-Release Capsules Phase III and Open-Label Extens

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

RYTARY TM (IPX066) (Carbidopa and Levodopa) Extended-Release Capsules Phase III and Open-Label Extension Data to be Presented at the American Academy of Neurology Conference

HAYWARD, Calif.–(BUSINESS WIRE)– Impax Pharmaceuticals, a division of Impax Laboratories, Inc. (NAS: IPXL) , today announced that data from the RYTARYTM Phase III and open-label extension trials will be presented at the 65th Annual Meeting of the American Academy of Neurology in San Diego, California, held from March 16 to March 23. IPX066 is an investigational extended-release capsule formulation of carbidopa-levodopa for the treatment of idiopathic Parkinson’s disease.

The presentation of IPX066 posters is as follows:

Date: March 18, 2013 (all posters)
Time: 2:00-6:30, with authors in attendance from 5:30-6:30 PM PT (all posters)
Location: San Diego Convention Center

Presentation Title and Number:
Long-Term Safety of IPX066 Extended-Release Carbidopa-Levodopa Capsules
in Patients with Motor Fluctuations in Advanced Parkinson’s Disease
Abstract / Poster Number: 3706/ P01.065

Presentation Title and Number:
Long-Term Safety of IPX066 Extended-Release Carbidopa-Levodopa Capsules
in Patients with Early Parkinson’s Disease
Abstract / Poster Number: 3662/ P01.064

Presentation Title and Number:
Analysis of IPX066 Dosing Data in Advanced Parkinson’s Disease (PD) Patients
Abstract / Poster Number: 49/ P01.063

About RYTARY TM (IPX066)

RYTARY is an investigational extended-release capsule formulation of carbidopa-levodopa for the treatment of idiopathic Parkinson’s disease. It is not approved or licensed anywhere in the world. Results from the phase III studies of RYTARY, APEX-PD (early PD), ADVANCE-PD (advanced PD) and ASCEND-PD (advanced PD) have previously been announced.

On January 21, 2013, Impax received a complete response letter which indicated that the FDA could not approve the NDA at that time. The complete response letter stated that satisfactory resolution and verification of the deficiencies identified during the inspection of the manufacturing facility in …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Ascent Capital Group, Inc. to Hold Annual Meeting of Shareholders

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Ascent Capital Group, Inc. to Hold Annual Meeting of Shareholders

ENGLEWOOD, Colo.–(BUSINESS WIRE)– Ascent Capital Group, Inc. (“Ascent” or the “Company”) (NAS: ASCMA) will be holding its Annual Meeting of Shareholders on Wednesday, May 22, 2013 at 10:00a.m., Mountain Time at 5251 DTC Parkway, Greenwood Village, Colorado 80111 ( the meeting will be held in the Second Floor Conference Room). The record date for the meeting is 5:00 p.m., New York City time, on April 3, 2013. At the meeting, Ascent may make observations regarding the Company’s financial performance and outlook.

About Ascent Capital Group, Inc.

Ascent is a holding company and owns 100 percent of its operating subsidiary, Monitronics International, Inc., one of the nation’s largest, fastest-growing home security alarm monitoring companies, headquartered in Dallas, Texas, and certain former subsidiaries of Ascent Media Group, LLC.

Sloane & Company
Erica Bartsch, 212-446-1875
ebartsch@sloanepr.com

KEYWORDS:   United States  North America  Colorado

INDUSTRY KEYWORDS:

The article Ascent Capital Group, Inc. to Hold Annual Meeting of Shareholders originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

(function(c,a){window.mixpanel=a;var b,d,h,e;b=c.createElement(“script”);
b.type=”text/javascript”;b.async=!0;b.src=(“https:”===c.location.protocol?”https:”:”http:”)+
‘//cdn.mxpnl.com/libs/mixpanel-2.2.min.js’;d=c.getElementsByTagName(“script”)[0];
d.parentNode.insertBefore(b,d);a._i=[];a.init=function(b,c,f){function d(a,b){
var c=b.split(“.”);2==c.length&&(a=a[c[0]],b=c[1]);a[b]=function(){a.push([b].concat(
Array.prototype.slice.call(arguments,0)))}}var g=a;”undefined”!==typeof f?g=a[f]=[]:
f=”mixpanel”;g.people=g.people||[];h=[‘disable’,’track’,’track_pageview’,’track_links’,
‘track_forms’,’register’,’register_once’,’unregister’,’identify’,’alias’,’name_tag’,
‘set_config’,’people.set’,’people.increment’];for(e=0;e<h.length;e++)d(g,h[e]);
a._i.push([b,c,f])};a.__SV=1.2;})(document,window.mixpanel||[]);
mixpanel.init("9659875b92ba8fa639ba476aedbb73b9");

function addEvent(obj, evType, fn, useCapture){
if (obj.addEventListener){
obj.addEventListener(evType, fn, useCapture);
return true;
} else if (obj.attachEvent){
var r = obj.attachEvent("on"+evType, fn);
return r;
…read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Colony Financial Announces Key Dates for Annual Meeting of Stockholders

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Colony Financial Announces Key Dates for Annual Meeting of Stockholders

LOS ANGELES–(BUSINESS WIRE)– Colony Financial, Inc. (NYS: CLNY) (the “Company”) today announced that it has scheduled its 2013 Annual Meeting of Stockholders for May 6, 2013. The record date for determination of stockholders entitled to vote at the meeting is March 25, 2013.

The meeting will be held at 9:00 a.m. ET on Monday, May 6, 2013, at the offices of Bank of America Merrill Lynch, located at Bank of America Tower, One Bryant Park (corner of 42nd Street and 6th Avenue), New York, New York 10036.

About Colony Financial, Inc.

Colony Financial, Inc. is a real estate investment and finance company that is focused on acquiring, originating and managing a diversified portfolio of opportunistic real estate-related debt and equity investments at attractive risk-adjusted returns. Our investment portfolio and target assets are primarily composed of interests in: (i) secondary loans acquired at a discount to par; (ii) new originations; and (iii) equity in single family homes to be held for investment and rented to tenants. Secondary debt purchases may include performing, sub-performing or non-performing loans (including loan-to-own strategies). Colony Financial has elected to be taxed as a real estate investment trust, or REIT, for U.S. federal income tax purposes. Colony Financial is a component of the Russell 2000® and the Russell 3000® indices. For more information, visit www.colonyfinancial.com.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by the use of forward-looking terminology such as “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” or “potential” or the negative of these words and phrases or similar words or phrases which are predictions of or indicate future events or trends and which do not relate solely to historical matters. Forward-looking statements involve known and unknown risks, uncertainties, assumptions and contingencies, many of which are beyond the Company’s control, that may cause actual results to differ significantly from those expressed in any forward-looking statement. Statements regarding the following subjects, among others, may be forward-looking: business and investment strategy; investment portfolio; projected operating results; ability to obtain financing …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Strayer Education, Inc. Hosts Investor Day May 1 – 2 in Herndon, Virginia

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Strayer Education, Inc. Hosts Investor Day May 1 – 2 in Herndon, Virginia

Registration Open

HERNDON, Va.–(BUSINESS WIRE)– Strayer Education, Inc. (NAS: STRA) today announced that it will host an Investor Day May 1-2, 2013, in Herndon, Virginia. The program will include a campus tour and panel discussion dinner with Strayer University students, alumni, and a corporate alliance partner, on Wednesday, May 1. On Thursday, May 2, immediately following the company’s Annual Meeting of Shareholders, the company will host presentations by members of the senior management team. The presentations will also be accessible via live webcast. For additional information and to register for Strayer Education‘s 2013 Investor Day, please visit the company’s website at www.strayereducation.com.

About Strayer Education, Inc.

Strayer Education, Inc. (NAS: STRA) is an education services holding company that owns Strayer University. Strayer’s mission is to make higher education achievable for working adults in today’s economy. Strayer University is a proprietary institution of higher learning that offers undergraduate and graduate degree programs in business administration, accounting, information technology, education, health services administration, public administration, and criminal justice to working adult students at 100 campuses in 24 states and Washington, D.C. and worldwide via the Internet. Strayer University also offers an executive MBA online through its Jack Welch Management Institute. Strayer University is committed to providing an education that prepares working adult students for advancement in their careers and professional lives. Founded in 1892, Strayer University is accredited by the Middle States Commission on Higher Education.

For more information on Strayer Education, Inc. visit www.strayereducation.com and for Strayer University visit www.strayer.edu.

Forward-Looking Statements

This press release contains statements that are forward-looking and are made pursuant to the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). Such statements may be identified by the use of words such as “expect,” “estimate,” “assume,” “believe,” “anticipate,” “will,” “forecast,” “plan,” “project,” or similar words. The statements are based on the Company’s current expectations and are subject to a number of assumptions, uncertainties and risks. In connection with the safe-harbor …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Osiris Therapeutics to Present at the Canaccord Genuity Musculoskeletal Conference

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Osiris Therapeutics to Present at the Canaccord Genuity Musculoskeletal Conference

COLUMBIA, Md.–(BUSINESS WIRE)– Osiris Therapeutics, Inc. (NAS: OSIR) , the leading stem cell company focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets, announced today that C. Randal Mills, Ph.D., President and Chief Executive Officer, is scheduled to present at the 2013 Canaccord Genuity Musculoskeletal Conference on Tuesday, March 19, 2013 at 9:30 a.m. ET (8:30 a.m. CT) in Chicago.

A live webcast of the presentation may be accessed through the Investors page of the Company’s website at www.Osiris.com. A replay of the webcast will be available for one week following the conference. Also, if in Chicago, please visit Osiris at booth 207 of McCormick Place for the Annual Meeting of The American Academy of Orthopaedic Surgeons, March 20-22.

About Osiris Therapeutics

Osiris Therapeutics, Inc., having developed the world’s first approved stem cell drug, Prochymal®, is the leading stem cell company. The company is focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets. In Biosurgery, Osiris currently markets Grafix® for acute and chronic wounds, and Ovation® and Cartiform for orthopedic applications. Osiris is a fully integrated company with capabilities in research, development, manufacturing and distribution of cellular products. Osiris has developed an extensive intellectual property portfolio to protect the company’s technology, including 50 U.S. and 156 foreign patents.

Osiris, Prochymal, Chondrogen, Grafix and Ovation are registered trademarks of Osiris Therapeutics, Inc. More information can be found on the company’s website, www.Osiris.com. (OSIR-G)

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include statements about our expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Words or phrases such as “anticipate,” “believe,” “continue,” “ongoing,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project” or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Examples of forward-looking statements may include, without limitation, statements regarding any of the following: our product development efforts; our clinical trials and anticipated regulatory requirements, and our ability to successfully navigate these requirements; the success of our product candidates in development; status of …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

ModusLink Announces Results of 2012 Annual Meeting and Completion of $30 Million Investment

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

ModusLink Announces Results of 2012 Annual Meeting and Completion of $30 Million Investment

WALTHAM, Mass.–(BUSINESS WIRE)– ModusLink Global Solutions™ Inc. (NAS: MLNK) today announced the certified voting results for ModusLink’s 2012 Annual Meeting of Stockholders (the “Annual Meeting“) held on March 12, 2013.

At the Annual Meeting, ModusLink stockholders voted to elect Warren G. Lichtenstein and Glen M. Kassan to the ModusLink Board of Directors as Class I directors.

In addition, ModusLink stockholders voted to approve the investment by Steel Partners Holdings L.P. (NYSE: SPLP, “Steel Holdings“), and the Company announced that the investment has been consummated. Under the previously announced Investment Agreement, Steel Holdings has purchased 7.5 million newly issued shares of common stock at a price of $4.00 per share, representing a cash investment in the Company, before fees and expenses, of $30 million. In addition, as part of the transaction, the Company has issued Steel Holdings warrants to acquire 2.0 million shares at an exercise price of $5.00 per share and Steel Holdings, together with certain affiliates, is allowed to purchase up to approximately 1.4 million shares of ModusLink’s outstanding common stock, subject to proportionate adjustment.

The investment transaction was consummated on March 12, 2013 and as agreed in the related settlement agreement, ModusLink Directors Edward E. Lucente and Joseph M. O’Donnell stepped down from the Board, and former Chairman Francis J. Jules and former Director and Audit Committee Chairman Michael J. Mardy, whose previous terms on the Board concluded at the Annual Meeting, were each reappointed to the Board as Class II directors. Mr. Lichtenstein will be designated Chairman of the Board of the Company in accordance with the settlement agreement.

ModusLink also reported the final results for the other proposals voted on at the Annual Meeting:

  • Approval on an advisory basis of the compensation of the Company’s named executive officers.
  • Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the current fiscal year.
  • Stockholders did not approve the proposal to amend the Company’s Restated Certificate of Incorporation to declassify the Board of Directors, which received approximately 52% of the outstanding shares in favor but which, under the Company’s Certificate of Incorporation, required 75% of such outstanding shares to be voted in favor in order to be approved.

…read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Philip Morris International Inc. (PMI) Announces Leadership Succession Plan

Leave a comment

By Business Wirevia The Motley Fool

Filed under:


Philip Morris International Inc. (PMI) Announces Leadership Succession Plan


Andre Calantzopoulos Appointed Chief Executive Officer


Louis Camilleri to Remain Chairman of the Board

NEW YORK–(BUSINESS WIRE)– Regulatory News:

The Board of Directors of Philip Morris International Inc. (NYSE / Euronext Paris: PM) today announced that André Calantzopoulos was appointed Chief Executive Officer to become effective immediately following the Annual Meeting of Shareholders on May 8, 2013. Mr. Calantzopoulos was also nominated for election to the Board of Directors at the Annual Meeting. He has served as PMI‘s Chief Operating Officer since the company’s spin-off on March 28, 2008. Louis Camilleri, PMI‘s current Chairman and Chief Executive Officer, will remain as Chairman of the Board and as an employee of the company.

Since the spin-off, Messrs. Camilleri and Calantzopoulos have worked closely together in their respective roles as Chief Executive Officer and Chief Operating Officer. Under their combined leadership, PMI has solidified its position as the largest and most profitable international tobacco company, while expanding its global market share, excluding China and the USA, to a record 28.8% in 2012. Among PMI‘s substantial achievements under their combined leadership since the spin-off through year-end 2012:

  • Total Shareholder Return of 103.5% versus the S&P 500 Index (20.6%);
  • Returned over $50 billion to shareholders through dividends and share repurchases;
  • Met, or exceeded, the high end of its adjusted diluted EPS annual growth target of 10-12%, excluding currency, each year;
  • Increased its dividend each year for a cumulative increase of 84.8%; and
  • Repurchased 489 million shares, or 23.2% of the shares outstanding after the spin-off, at an average price of $56.96 per share.

Lucio A. Noto, PMI‘s independent Presiding Director, said: “Louis has assembled and led a tremendous …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Acorda to Present New Research on Novel Multiple Sclerosis and Epilepsy Therapies at American Academ

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Acorda to Present New Research on Novel Multiple Sclerosis and Epilepsy Therapies at American Academy of Neurology 65 th Annual Meeting

ARDSLEY, N.Y.–(BUSINESS WIRE)– Acorda Therapeutics, Inc. (Nasdaq: ACOR) will present new research data at the 65th American Academy of Neurology Annual Meeting on AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg, an FDA-approved therapy indicated to improve walking in people with multiple sclerosis, and Diazepam Nasal Spray, an investigational therapy for the treatment of cluster seizures, also known as acute repetitive seizures, in people with epilepsy.

“Acorda is focused on improving the lives of people with neurological disorders. We currently are developing seven therapies for a range of conditions, including multiple sclerosis, epilepsy and spinal cord injury,” said Ron Cohen, M.D., Acorda Therapeutics’ President and CEO. “Our presentations at AAN include new studies on AMPYRA and the first clinical data presented on Diazepam Nasal Spray. These studies have increased our understanding of the potential roles these therapies could have in addressing the urgent needs of patients with these conditions.”

Data being presented on Acorda-developed therapies at the AAN annual meeting include:

  • Changes in Gait, Walking, and Balance Parameters After Withdrawal and Re-initiation of Dalfampridine Extended Release Tablets in Patients with Multiple Sclerosis: Results from the STEADY Study – P04.103 being presented Wednesday, March 20th, 7:30am – 12:00pm
  • Safety and Efficacy of 5mg and 10mg Dalfampridine Extended Release Tablets in Patients with Multiple Sclerosis: First Results from a Double-Blind, Placebo-Controlled Trial – P04.096 being presented Wednesday, March 20th, 7:30am – 12:00pm
  • Effects of 5mg and 10mg Dalfampridine Extended Release Tablets on 6-Minute Walk Distance in People with Multiple Sclerosis: A Subgroup Analysis of a Double-Blind, Placebo-Controlled Trial – S01.007 being presented Tuesday, March 19th at 2:30pm
  • Assessment of Pharmacokinetic Linearity and Relative Bioavailability of a Nasal Diazepam Formulation Compared with Diazepam Rectal Gel In Healthy Adult Subjects – P02.214 being presented Tuesday, March 19th, 7:30am – 12:00pm

More detailed information on scientific sessions and data presentations at the AAN annual meeting can be found on the conference website (http://www.aan.com/go/am13).

Important Safety Information

Do not take AMPYRA if you have ever had a seizure or have certain types of kidney problems.

Take AMPYRA exactly as prescribed by your doctor.

…read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

NuStar GP Holdings Announces Election of New Director

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

NuStar GP Holdings Announces Election of New Director

SAN ANTONIO–(BUSINESS WIRE)– The board of directors of NuStar GP Holdings (NYS: NSH) has nominated Jelynne LeBlanc Burley for a position on the company’s board. The election will occur at the company’s Annual Meeting of Unitholders at 10:30 a.m. (CT) Wednesday, April 24 at NuStar’s corporate office at 19003 IH-10 West in San Antonio.

Burley is Executive Vice President-Corporate Support Services and Chief Administrative Officer of CPS Energy, the nation’s largest municipally owned energy company providing both natural gas and electric service to the San Antonio area.

“Jelynne will be a great asset to our board because of her experience in the energy industry, her strong leadership skills and her sound business judgment,” said Bill Greehey, chairman of the board of NuStar GP Holdings. “As NuStar undertakes its most ambitious plan for growth, Jelynne’s experience overseeing strategic planning, developing and managing budgets, leading multi-million-dollar construction projects, and managing hundreds of employees will be invaluable.”

Burley joined CPS in 2008 as Senior Vice President & Chief Administrative Officer, and was subsequently named Acting General Manager and promoted to her current position as Executive Vice President & CAO. During her tenure, Burley has helped ensure the utility company’s future viability, prosperity and long-term success in terms of financial strength, environmental stewardship and community support by helping to establish strategic partnerships and alliances. A few of her achievements include helping to set the organization’s new strategic direction, re-establishing a stable outlook from the bond rating agencies, strengthening public trust in the utility, and obtaining unanimous approval for a new rate structure.

Prior to joining CPS, Burley spent nearly 25 years in various leadership positions with the City of San Antonio, which is the 7th largest city in the U.S. She spent six years serving as Assistant City Manager and then Deputy City Manager where she directed everything from Planning & Development, Public Works and International Affairs, to Economic Development, Information Services and Housing and Neighborhood Services.

Before joining the City Manager’s Office, Burley served as the city’s Director of Facilities Planning and Construction, and she held positions of increasing responsibility in project management and budget and management.

She serves on the board of directors of the National Forum for Black Public Administrators, and she’s a current board member and past president, secretary and treasurer of Urban Management Assistants of South Texas. She’s also involved with the American Public Power Association, the Large Public Power Council, …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

InSite Vision Announces Date for Annual Shareholder Meeting

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

InSite Vision Announces Date for Annual Shareholder Meeting

ALAMEDA, Calif.–(BUSINESS WIRE)– InSite Vision Incorporated (OTCBB: INSV), a company developing ophthalmic products for unmet eye care needs, today announced that the company’s Annual Meeting of Stockholders will be held at 10:00 a.m. Pacific Time on Wednesday, May 29, 2013, for shareholders of record on April 3, 2013. The Annual Meeting will be held at InSite Vision’s headquarters at 965 Atlantic Avenue, Alameda, California. InSite Vision plans to mail the definitive proxy statement for the Annual Meeting, as well as its annual report, in April.

About InSite Vision

InSite Vision is advancing new ophthalmologic products for unmet eye care needs based on its innovative DuraSite® platform technologies. The DuraSite and DuraSite 2 drug delivery systems extend the duration of drug retention on the surface of the eye, thereby reducing the frequency of treatment and improving the efficacy of topical drugs.

The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite® (azithromycin ophthalmic solution) 1%, marketed in the U.S. by Merck, and Besivance® (besifloxacin ophthalmic suspension) 0.6%, marketed by Bausch + Lomb. InSite Vision is also advancing three novel ophthalmic therapeutics through Phase 3 clinical studies: AzaSite Plus™ and DexaSite™ for the treatment of eye infections, and BromSite™ for pain and inflammation associated with ocular surgery. For further information on InSite Vision, please visit www.insitevision.com.

AzaSite®, DuraSite® and DuraSite 2® are registered trademarks of InSite Vision Incorporated.

AzaSite Plus™, BromSite™ and DexaSite™ are trademarks of InSite Vision Incorporated.

BESIVANCE® is a registered trademark of Bausch + Lomb Incorporated.

InSite Vision
Louis Drapeau, 510-747-1220
Chief Financial Officer
mail@insite.com
or
Media/Investor Inquiries:
BCC Partners
Michelle Corral, 415-794-8662

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:

The article InSite Vision Announces Date for Annual Shareholder Meeting originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 – 2013 The Motley Fool, LLC. All …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Infinity Provides Company Update and Reports Full-Year 2012 Financial Results

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Infinity Provides Company Update and Reports Full-Year 2012 Financial Results

– Cohort Expansions of Phase 1 Trial of IPI-145 in Patients with Advanced Hematologic Malignancies Now Enrolling –

– Key Data Expected from PI3K and Hsp90 Programs in 2013 –

CAMBRIDGE, Mass.–(BUSINESS WIRE)– Infinity Pharmaceuticals, Inc. (NAS: INFI) reported its full-year 2012 financial results and ongoing progress with IPI-145, its potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, and retaspimycin HCl, its potent and selective inhibitor of heat shock protein 90 (Hsp90), and anticipates reporting clinical data from both these programs this year. Infinity also announced today that it initiated five new expansion cohorts in its trial of IPI-145 in patients with advanced hematologic malignancies.

“We made important progress on our product development goals last year, reporting encouraging preliminary data from our Phase 1 trial of IPI-145 in patients with advanced hematologic malignancies, initiating a Phase 2a trial of IPI-145 in patients with asthma, and completing enrollment in our Phase 2, double-blind, randomized, placebo-controlled trial of retaspimycin HCl in non-small cell lung cancer,” stated Adelene Q. Perkins, Infinity’s president and chief executive officer. “We entered 2013 in a strong financial position with approximately $327 million in cash and investments and anticipate this will be a year of fundamental progress for Infinity, as data generated from our ongoing trials will inform our potential registration paths as we continue building a sustainable, fully-integrated biopharmaceutical company.”

In December 2012, Infinity reported encouraging preliminary data at the Annual Meeting of the American Society for Hematology (ASH) showing clinical activity at each of the doses of IPI-145 evaluated from 8 mg through 75 mg twice daily (BID), indicating a potential broad therapeutic window. Infinity has now defined 75 mg BID as the maximum tolerated dose and has leveraged the adaptive approach of its Phase 1 trial to continue to explore the safety, pharmacokinetics and activity of IPI-145 at 75 mg BID in five additional expansion cohorts of patients with the following hematologic malignancies:

1. Chronic lymphocytic leukemia, indolent non-Hodgkin lymphoma and mantle cell lymphoma
2. T-cell lymphomas
3. Aggressive B-cell lymphomas
4. Myeloid neoplasms
5. T-cell or B-cell acute lymphoblastic leukemia/lymphoma

“We are pleased to have completed the dose-escalation phase of our Phase 1 trial of IPI-145, enabling us to initiate additional expansion cohorts …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

The Toro Company to Webcast its Annual Meeting of Shareholders

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

The Toro Company to Webcast its Annual Meeting of Shareholders

BLOOMINGTON, Minn.–(BUSINESS WIRE)– The Toro Company (NYS: TTC) will hold its 2013 Annual Meeting of Shareholders on Tuesday, March 12, 2013, at 1:30 p.m. CDT.

A live, listen-only webcast of the meeting will be available at www.thetorocompany.com under Investor Information. Individuals are advised to go to the website at least 15 minutes early to register, download and install any necessary audio software.

For those unable to participate in the live broadcast, a replay will be available at www.thetorocompany.com/invest until April 1. There is no charge to access the webcast.

About The Toro Company

The Toro Company (NYS: TTC) is a leading worldwide provider of innovative turf, landscape, rental and construction equipment, and irrigation and outdoor lighting solutions. With sales of more than $1.9 billion in fiscal 2012, Toro’s global presence extends to more than 90 countries through strong relationships built on integrity and trust, constant innovation, and a commitment to helping customers enrich the beauty, productivity and sustainability of the land. Since 1914, the company has built a tradition of excellence around a number of strong brands to help customers care for golf courses, sports fields, public green spaces, commercial and residential properties, and agricultural fields. More information is available at www.thetorocompany.com.

The Toro Company
Investor Relations:
Kurt Svendsen, 952-887-8630
Managing Director, Corporate Communications and Investor Relations
kurt.svendsen@toro.com
or
Media Relations:
Branden Happel, 952-887-8930
Senior Manager, Public Relations
branden.happel@toro.com

KEYWORDS:   United States  North America  Minnesota

INDUSTRY KEYWORDS:

The article The Toro Company to Webcast its Annual Meeting of Shareholders originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

(function(c,a){window.mixpanel=a;var b,d,h,e;b=c.createElement(“script”);
b.type=”text/javascript”;b.async=!0;b.src=(“https:”===c.location.protocol?”https:”:”http:”)+
‘//cdn.mxpnl.com/libs/mixpanel-2.2.min.js’;d=c.getElementsByTagName(“script”)[0];
…read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Senesco Technologies Provides Corporate Update

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Senesco Technologies Provides Corporate Update

SNS01-T Clinical Trial Proceeding

New Preclinical Results in Liver Cancer Models

BRIDGEWATER, N.J.–(BUSINESS WIRE)– Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTCQB: SNTI) provides the following update on Company activities.

Financial Update

As of December 31st, 2012, Senesco had cash and cash equivalents of $640,125, which was complemented in January 2013 by the receipt of approximately $2,300,000 in net proceeds from the issuance of common stock and warrants. Since November 2012, the Company’s common stock has been quoted on the OTCQB under the ticker symbol SNTI. During the first two months of 2013, average trading volumes increased significantly to over a million shares on certain days. The Company believes this is linked to the January issuance of registered common stock and the need for certain investors to change how their Company OTCQB-quoted stock is held in their accounts.

We recently mailed our proxy statement to stockholders in preparation for the Annual Meeting of Shareholders on March 28th, 2013. One of the proposals included in the proxy statement would give the Company’s board of directors the option to shrink the number of outstanding shares via a reverse split in any ratio of between 2:1 and 20:1 in order to assist in the Company’s efforts to regain the listing of the Company’s common stock on an NYSE or NASDAQ exchange and assist in the Company’s future fund raising efforts. However the timing and the actual ratio of the reverse split have not yet been set and would be determined based on market conditions.

We believe that a well-implemented reverse split could benefit our stockholders by:

…read more
Source: FULL ARTICLE at DailyFinance